-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Buux9HjJ508mP0QwHQUZ51clHIga6G3+4BUY5NrE/5+JWQ5PzezLvq6o+teHS/dX o8z90kEPq1L6f8GArJINGQ== 0001286774-09-000005.txt : 20090911 0001286774-09-000005.hdr.sgml : 20090911 20090910203043 ACCESSION NUMBER: 0001286774-09-000005 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506 FILED AS OF DATE: 20090911 DATE AS OF CHANGE: 20090910 EFFECTIVENESS DATE: 20090911 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ONDINE BIOPHARMA CORP CENTRAL INDEX KEY: 0001286774 IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-64540 FILM NUMBER: 091063833 BUSINESS ADDRESS: STREET 1: 910-1100 MELVILLE ST CITY: VANCOUVER STATE: A1 ZIP: V6E 4A6 BUSINESS PHONE: 604-669-0555 MAIL ADDRESS: STREET 1: 910-1100 MELVILLE ST CITY: VANCOUVER STATE: A1 ZIP: V6E 4A6 D 1 primary_doc.xml X0502 D LIVE 0001286774 ONDINE BIOPHARMA CORP 910-1100 MELVILLE ST VANCOUVER A1 V6E 4A6 604-669-0555 None BRITISH COLUMBIA, CANADA Corporation true Carolyn Cross 910-1100 Melville Street Vancouver A1 V6E 4A6 Executive Officer Director Terence Holland 910-1100 Melville Street Vancouver A1 V6E 4A6 Director Colin Watt 910-1100 Melville Street Vancouver A1 V6E 4A6 Director Michael Crane 910-1100 Melville Street Vancouver A1 V6E 4A6 Director William Harper 910-1100 Melville Street Vancouver A1 V6E 4A6 Executive Officer Thomas Dawson 910-1100 Melville Street Vancouver A1 V6E 4A6 Executive Officer Margaret Shaw 910-1100 Melville Street Vancouver A1 V6E 4A6 Director Nicholas Loebel 910-1100 Melville Street Vancouver A1 V6E 4A6 Executive Officer Biotechnology $1 - $1,000,000 06 false 2009-06-24 false true false 0 43360 43360 0 454,545 units at C$0.11 each of 1 common share + 1 warrant exercisable C$0.15 each for 1 common share until June 26, 2011 issued pursuant to Subsription Agreement with a U.S. accredited investor, exchange rate Cdn $1.00 to $0.8672 US$ 06/26 BofC rate false 1 0 0 0 false ONDINE BIOPHARMA CORP William S. Harper William Harper CFO 2009-09-10 -----END PRIVACY-ENHANCED MESSAGE-----